Latest Breaking News On - Division of surgical oncology research - Page 1 : comparemela.com

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

San diegoUnited statesSan diego convention centerDaniel kontoh boatengKarolinska institutetElisa ruffoDave mehalickJason lohmuellerSecurities exchangeCoeptis therapeutics incHoldings incExchange commissionCoeptis pharmaceuticals incDrug administrationCoeptis therapeutics holdings incDivision of surgical oncology research

Coeptis Therapeutics (COEP) Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Coeptis Therapeutics (COEP) Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jason lohmuellerDaniel kontoh boatengDavid schemeliaKarolinska institutetVygen bioDave mehalickUniversity of pittsburghDivision of surgical oncology researchCoeptis pharmaceuticals incTiberend strategic advisors incCoeptis therapeutics holdings incDrug administrationExchange commissionSecurities exchangeCoeptis therapeutics incCoeptis therapeutics holdings

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

Jason lohmuellerKarolinska institutetVygen bioDaniel kontoh boatengDave mehalickDavid schemeliaCoeptis therapeutics incSecurities exchangeUniversity of pittsburghDivision of surgical oncology researchCoeptis therapeutics holdings incHoldings incExchange commissionPrnewswire coeptis therapeutics holdings incDrug administrationCoeptis pharmaceuticals inc

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jon nugentDavid schemeliaJason lohmuellerKarolinska institutetDave mehalickDivision of surgical oncology researchCoeptis pharmaceuticals incPrnewswire coeptis therapeutics holdings incExchange commissionCoeptis therapeutics holdings incCoeptis therapeutics incSecurities exchangeHoldings incUniversity of pittsburghNature communicationsDrug administration

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

Jon nugentDave mehalickJason lohmuellerKarolinska institutetDavid schemeliaCoeptis pharmaceuticals incUniversity of pittsburghDrug administrationPrnewswire coeptis therapeutics holdings incNature communicationsCoeptis therapeutics incCoeptis therapeutics holdings incSecurities exchangeHoldings incDivision of surgical oncology researchExchange commission